Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

Yudin, Andrei (University of Toronto)

$121,000.00

Oxadiazole grafts in peptide macrocycles

FY 2017-18 · 2018-02-07

Summary
In 2016, we discovered a macrocyclization reaction that rapidly converts readily accessible linear peptides into macrocycles with well-defined conformation. (N-isocyanimino)triphenylphosphorane, instrumental to this reaction, was later named "Pinc" to identify the presence of phosphonium and isocyanide functionalities. This work was published in Nature Chemistry and was subsequently covered by The Chemical & Engineering News and Science. On the heels of this discovery, we applied for a patent application (PCT/CA2016/000234) that described the method of cyclizing peptides with simultaneous incorporation of an oxadiazole graft into the resulting macrocyclic structures. We also received market assessment funding from NSERC allowing us to retain the services of Adventus Research who carried out a thorough market assessment study (see the 85-page report attached)._x000D_ _x000D_ The present I2I application considers the main messages from that report and focuses on two applications that will further de-risk our technology now that it is sufficiently mature. The first one is to develop an approach to the synthesis of improved derivatives of Pinc. The second one deals with peptide macrocycles produced using Pinc in order to further validate our approach to novel composition of matter. To move forward, we will engage in collaborative activity to produce Pinc (together with MilliporeSigma), initiate translational studies aimed at the use of Pinc toward heterocycle synthesis (together with Apotex), and evaluate the potential of Pinc-derived macrocycles in drug discovery (together with Encycle and Merck)._x000D_
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
Proactive Disclosure - Grants and Contributions

As published

Additional Information
Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).
Additional Information (French)
Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).
Agreement Number
I2IPJ
Agreement Start Date
2018-02-07
Agreement Title
Oxadiazole grafts in peptide macrocycles
Agreement Title (French)
Oxadiazole grafts in peptide macrocycles
Agreement Type
Grant
Agreement Value
$121,000.00
Amendment Number
0
Organization Code
nserc-crsng
Organization
Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada
Program Name
Idea to Innovation
Program Name (French)
De l'idée à l'innovation
Program Purpose
In 2016, we discovered a macrocyclization reaction that rapidly converts readily accessible linear peptides into macrocycles with well-defined conformation. (N-isocyanimino)triphenylphosphorane, instrumental to this reaction, was later named "Pinc" to identify the presence of phosphonium and isocyanide functionalities. This work was published in Nature Chemistry and was subsequently covered by The Chemical & Engineering News and Science. On the heels of this discovery, we applied for a patent application (PCT/CA2016/000234) that described the method of cyclizing peptides with simultaneous incorporation of an oxadiazole graft into the resulting macrocyclic structures. We also received market assessment funding from NSERC allowing us to retain the services of Adventus Research who carried out a thorough market assessment study (see the 85-page report attached)._x000D_ _x000D_ The present I2I application considers the main messages from that report and focuses on two applications that will further de-risk our technology now that it is sufficiently mature. The first one is to develop an approach to the synthesis of improved derivatives of Pinc. The second one deals with peptide macrocycles produced using Pinc in order to further validate our approach to novel composition of matter. To move forward, we will engage in collaborative activity to produce Pinc (together with MilliporeSigma), initiate translational studies aimed at the use of Pinc toward heterocycle synthesis (together with Apotex), and evaluate the potential of Pinc-derived macrocycles in drug discovery (together with Encycle and Merck)._x000D_
Program Purpose (French)
In 2016, we discovered a macrocyclization reaction that rapidly converts readily accessible linear peptides into macrocycles with well-defined conformation. (N-isocyanimino)triphenylphosphorane, instrumental to this reaction, was later named "Pinc" to identify the presence of phosphonium and isocyanide functionalities. This work was published in Nature Chemistry and was subsequently covered by The Chemical & Engineering News and Science. On the heels of this discovery, we applied for a patent application (PCT/CA2016/000234) that described the method of cyclizing peptides with simultaneous incorporation of an oxadiazole graft into the resulting macrocyclic structures. We also received market assessment funding from NSERC allowing us to retain the services of Adventus Research who carried out a thorough market assessment study (see the 85-page report attached)._x000D_ _x000D_ The present I2I application considers the main messages from that report and focuses on two applications that will further de-risk our technology now that it is sufficiently mature. The first one is to develop an approach to the synthesis of improved derivatives of Pinc. The second one deals with peptide macrocycles produced using Pinc in order to further validate our approach to novel composition of matter. To move forward, we will engage in collaborative activity to produce Pinc (together with MilliporeSigma), initiate translational studies aimed at the use of Pinc toward heterocycle synthesis (together with Apotex), and evaluate the potential of Pinc-derived macrocycles in drug discovery (together with Encycle and Merck)._x000D_
Recipient City
Ontario
Recipient Country
CA
Recipient Legal Name
Yudin, Andrei (University of Toronto)
Reference Number
GC-2017-Q4-01964